Complete response of early gastric cancer to uracil and tegafur

Journal of Gastroenterology

Volumn 33, Issue 6, 1998, Pages 864-867

  Akahoshi, Kazuya ^a,b   Chijiiwa, Yoshiharu ^a   Hamada, Syuji ^a   Hara, Keiichi ^a   Nakamura, Kazuhiko ^a   Nawata, Hajime ^a   Matsui, Noriaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Complete response; Early gastric cancer; UFT

Indexed keywords

TEGAFUR; URACIL;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; EARLY CANCER; ENDOSCOPIC BIOPSY; ENDOSCOPIC ECHOGRAPHY; FEMALE; GASTROSCOPY; HUMAN; ISCHEMIC HEART DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTROSCOPY; HUMANS; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0032466298     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050189     Document Type: Article

References (26)

1. Yamao T, Shirao K, Ono H, et al. Risk factors for lymph node metastasis from intramucosal gastric cancer. Cancer 1996;77:602-606.
2. Maehara Y, Orita H, Okuyama T, et al. Predictors of lymph node metastasis in early gastric cancer. Br J Surg 1992;79:245-247.
3. Baba H, Maehara Y, Okuyama T, et al. Lymph node metastasis and macroscopic features in early gastric cancer. Hepatogastroenterology 1994;41:380-383.
4. Tada M, Murakami A, Karita M, et al. Endoscopic resection of early gastric cancer. Endoscopy 1993;25:445-450.
5. Takekoshi T, Baba Y, Ota H, et al. Endoscopic resection of early gastric carcinoma: Results of a retrospective analysis of 308 cases. Endoscopy 1994;26:352-358.
6. Maehara Y, Watanabe A, Kakeji Y, et al. Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric cancer. Am J Surg 1990;160:242-244.
7. Kitamura K, Beppu R, Anai H, et al. Clinicopathologic study of patients with Borrmann type IV gastric carcinoma. J Surg Oncol 1995;58:112-117.
8. Kumagai K, Yasui A, Nishida Y, et al. The significance of preoperative chemotherapy for early gastric carcinoma. Surg Today 1993;20:875-879.
9. Rougier Ph, Lasser Ph, Durceux M, et al. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994;5:59-68.
10. Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
11. Gebbia V, Valenza R, Testa A, et al. Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: Experience with a lower dose schedule. J Cancer Res Clin Oncol 1994;120:550-552.
12. Pyrhönen S, Kuitunen T, Kouri M. A randomized phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FAMtx) with best supportive care in non-resectable gastric cancer (abstract). Ann Oncol 1992;3:47.
13. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
14. Feliu J, Baron MG, Zamora P, et al. Experience of oncopaz cooperative group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology 1997;54:30-37.
15. Kim NK, Park YS, Hoe DS, et al. A phase III randomized study of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
16. Yamauchi S, Hirata T, Tsuruhara Y. A case of unresectable gastric cancer with liver metastases which responded to oral administration of UFT (in Japanese). Jpn J Cancer Chemother 1986;13:384-388.
17. Sato T, Nio Y, Seshimo T, et al. Neoadjuvant chemotherapy with UFT for gastric cancer (second report) (in Japanese). J Jpn Soc Cancer Ther 1996;31:1019-1029.
18. Fujii S, Ikenaka K, Fukushima M, et al. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahidrofuryl)-5-fluorouracil. Gann 1978;69:763-772.
19. Kimura K, Suga S, Shimaji T, et al. Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2′-tetrahydrofuryl)-5-fluorouracil. Gastroenterol Jpn 1980;15:324-329.
20. Ikenaka K, Shirasaka T, Kitano S, et al. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1981;72:590-597.
21. Hanaue H, Kurosawa T, Kitano Y, et al. Anticancer drug distribution in lymph and blood during adjuvant chemotherapy after surgery for gastric carcinoma. Cancer 1987;59:1571-1576.
22. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333-338.
23. Maehara Y, Kusumoto T, Kusumoto H, et al. UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil. Chemotherapy 1988;34:484-489.
24. Damhuis RAM, Tilanus HW. The influence of age on resection rates and postoperative mortality in 2773 patients with gastric cancer. Eur J Cancer 1995;31A:928-931.
25. Kimose HH, Lund O, Hasenkam JM, et al. Independent predictors of operative mortality and postoperative complications in surgically treated carcinomas of the oesophagus and cardia: Is the aggressive surgical approach worthwhile? Acta Chir Scand 1990;156:373-382.
26. Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: Biochemical modulation for 5-FU. Oncology 1997;54:12-18.